Global TNF Inhibitors Market | 10% CAGR Projection Over the Next Four Years | Technavio

ELMHURST, Ill. - Nov. 26, 2019 - PRLog -- The global tumor necrosis factor (TNF) inhibitors market is expected to post a CAGR of close to 10% during the forecast period, according to the latest market research report by Technavio.

A key factor driving the growth of the market is the increasing prevalence of autoimmune disorders such as rheumatoid arthritis, psoriasis, and Chron's disease. The prevalence of arthritis such as rheumatoid arthritis is higher in women than in men, and it increases with age. Moreover, the increasing incidence of the disorder is expected to increase significantly in women and is expected to constitute about two-thirds of the overall patient population with arthritis.

This market research report on the global TNF inhibitors market 2019-2023 also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.

Download the free sample report @ https://www.technavio.com/talk-to-us?report=IRTNTR31768&type=sample&src=report&utm_source=off-page&utm_medium=pr&utm_campaign=2019-ch-W30

Global TNF inhibitors market: Advent of biosimilars

Currently, the global TNF inhibitors market has five approved biologics, and the market has witnessed an increase in the number of biosimilars, as many of the approved biologics are nearing patent expiration. Various vendors are focusing on developing biosimilars owing to the high efficacy and safety of the biological drugs that are approved for the treatment of various autoimmune diseases. About 50 biosimilars are currently developed for the treatment of various indications, with a good share of the biosimilars being developed for the treatment of autoimmune disorders.

"Biosimilars are comparatively cost-effective than biological drugs and are known to be preferred heavily due to the ease of access, the similar efficacy of original biologics, and the low prices associated with them. Also, these biosimilars get preferred treatment from regulatory authorities for their approval and launch, as they result in cost savings for the federal health care budget,"

Get the Complete Report @ https://www.technavio.com/report/global-tnf-inhibitors-market-industry-analysis?utm_source=off-page&utm_medium=pr&utm_campaign=2019-ch-W30

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100